4 not yet recruiting, 3 unknown, 2 recruiting, 2 terminated. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Not yet recruiting 4, Unknown 3, Recruiting 2, Terminated 2, Completed 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow SBRT: new trials by email Literature Review of SBRT trials Research Report on SBRT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy - EGFR-mutant Non-small Cell Lung Cancer, SBRT | Phase 2 | Not yet recruiting | Fudan University | 374 | 2026-10-01 | 2026-09-16 |
| ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan - Adenoid Cystic Carcinoma of the Head and Neck, SBRT | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-05-01 | 2026-05-12 |
| Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Benmelstobart, SBRT, Anlotinib - Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 29 | 2026-04-20 | 2026-04-17 |
| SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma adbelimumab, SBRT, apatinib - Hepatocellular Carcinoma, SBRT | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 80 | 2025-01-01 | 2024-08-06 |
| SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy SBRT combined with Nimotuzumab followed by Tislelizumab - Nasopharyngeal Cancinoma (NPC), SBRT | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2024-11-05 | 2025-07-01 |
| SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx SBRT+chemoimmunotherapy - SBRT | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2023-12-07 | 2024-03-12 |
| Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy Pre-therapeutic imaging test - SBRT, Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | University Hospital, Brest | 60 | 2021-07-15 | 2022-09-19 |
| Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Drug GC4711, Placebo - SBRT, Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Galera Therapeutics, Inc. | 177 | 2021-05-07 | 2024-05-21 |
| Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC GC4711 +SBRT, Placebo +SBRT - SBRT, NSCLC | Phase 1 / Phase 2 | Terminated | Galera Therapeutics, Inc. | 47 | 2020-10-18 | 2024-04-30 |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC Stereotactic body radiation therapy, Anti-PD-1 antibody drug named Sintilimab - Stage IV HCC, Immunotherapy | Phase 2 | Unknown | West China Hospital | 84 | 2020-07-01 | 2020-09-14 |
| Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. - Cancer of Pancreas, Unresectable Pancreatic Cancer | Phase 2 | Completed | Medical University of Silesia | 40 | 2017-01-01 | 2019-11-13 |
| SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations SBRT concurrent with GM-CSF, two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel - NSCLC, SBRT | Phase 2 | Unknown | Shanghai Chest Hospital | 50 | 2016-11-01 | 2016-12-01 |
Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Liver Diseases (2) · Liver Neoplasms (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2)
Radiosurgery (2) · Cisplatin (1) · Fluorouracil (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Irinotecan (1) · Oxaliplatin (1) · Pancreatectomy (1) · Platinum (1) · Surgical Procedures, Operative (1) · anlotinib (1) · apatinib (1)
Galera Therapeutics, Inc. (2) · Fudan University (1) · Fujian Cancer Hospital (1) · Medical University of Silesia (1) · Nanfang Hospital, Southern Medical University (1) · Shanghai Chest Hospital (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Xiamen University (1) · University Hospital, Brest (1) · West China Hospital (1)
China (5) · France (2) · United States (2) · Canada (1) · Poland (1) · United Kingdom (1)
Chen Jinzhang (1) · Eugene P Kennedy, MD (1)
PMID 34145168, PMID 22560555, PMID 26095785, PMID 26484629, PMID 26582738, PMID 26951040, PMID 38039992, PMID 38264869, PMID 40591115